Mecolvix (Mesalazine)

Mesalazine inhibits cyclooxygenase and lipoxygenase enzymes in the colonic mucosa, lowering the production of prostaglandins and leukotrienes. This suppression of inflammatory mediators reduces local inflammation, promotes mucosal healing, and alleviates the symptoms of ulcerative colitis.

The dose of Mecolvix is individualized by the prescribing clinician based on disease severity, location, and patient response. Healthcare professionals determine the appropriate amount and frequency, and patients should follow the prescriber’s instructions without alteration.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative therapies when possible. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Mecolvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Mecolvix (mesalazine) belongs to the aminosalicylate class, offering a topical anti‑inflammatory effect directly in the colon. Compared with systemic steroids or biologics, it has a more favorable safety profile for long‑term maintenance but may be less potent in severe disease, where escalation to immunomodulators or biologics might be required.

Mecolvix should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mecolvix is administered rectally, typically as a suppository or enema, allowing direct delivery of mesalazine to the distal colon. Patients should follow the prescriber’s instructions on insertion technique, timing, and frequency to achieve optimal therapeutic effect.

Serious risks include severe allergic reactions such as anaphylaxis, significant rectal bleeding, acute colitis flare, and rare cases of liver or kidney toxicity. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, blood in stool, jaundice, or sudden worsening of abdominal pain.

Mecolvix is contraindicated in individuals with known hypersensitivity to mesalazine, other aminosalicylates, or salicylate compounds. It should also be avoided in patients with severe ulcerative colitis requiring systemic therapy, and caution is advised in those with compromised renal or hepatic function.